Cyclooxygenase-2: a therapeutic target.

  • Turini M
  • DuBois R
  • 88


    Mendeley users who have this article in their library.
  • 464


    Citations of this article.


Cyclooxygenase (COX), also known as prostaglandin endoperoxide synthase, is the key enzyme required for the conversion of arachidonic acid to prostaglandins. Two COX isoforms have been identified, COX-1 and COX-2. In many situations, the COX-1 enzyme is produced constitutively (e.g., in gastric mucosa), whereas COX-2 is highly inducible (e.g., at sites of inflammation and cancer). Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both enzymes, and a new class of COX-2 selective inhibitors (COXIBs) preferentially inhibit the COX-2 enzyme. This review summarizes our current understanding of the role of COX-1 and COX-2 in normal physiology and disease.

Author-supplied keywords

  • Anti-Inflammatory Agents
  • Clinical Trials as Topic
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Cyclooxygenase Inhibitors: adverse effects
  • Cyclooxygenase Inhibitors: therapeutic use
  • Humans
  • Inflammation
  • Inflammation: drug therapy
  • Inflammation: enzymology
  • Isoenzymes
  • Isoenzymes: antagonists & inhibitors
  • Membrane Proteins
  • Neoplasms
  • Neoplasms: drug therapy
  • Neoplasms: enzymology
  • Non-Steroidal
  • Non-Steroidal: adverse e
  • Non-Steroidal: therapeut
  • Prostaglandin-Endoperoxide Synthases

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Marco E Turini

  • Raymond N DuBois

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free